Here is a brief preview of this blast: On Friday, September 15, the CHMP meeting highlights were released. Of note, Carvykti (JNJ / Legend’s BCMA CAR-T) was absent from the CHMP highlights implying that it has received a Request for Supplementary Information (RSI) for its assessment in ≥2L MM. Moreover, recall that Abecma (BMS / 2seventy’s BCMA CAR-T) was not included on Monday’s CHMP agenda. Below, Celltelligence provides insights on the September CHMP meeting with updated EU regulatory timelines for both cell therapies. 

About The Author

The Celltelligence Team

|

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.